Back to today’s briefing

Story perspectives

FDA Approves Symbravo: New Hope for Migraine Relief

2/1/2025

39 7

Summary

Story summary

The FDA has greenlit Symbravo, a powerful blend of rizatriptan and meloxicam, to tackle acute migraines in adults. Set to hit the market in just four months, this innovative treatment demonstrated swift pain relief in trials, with many patients avoiding additional medication within a day. With over 39 million Americans affected by migraines, hope is on the horizon.

1 of 1

Story summary

The FDA has greenlit Symbravo, a powerful blend of rizatriptan and meloxicam, to tackle acute migraines in adults. Set to hit the market in just four months, this innovative treatment demonstrated swift pain relief in trials, with many patients avoiding additional medication within a day. With over 39 million Americans affected by migraines, hope is on the horizon.